Uveal melanoma and metastatic liver disease
Research activity in metastatic uveal melanoma with resectable liver metastasis and disease confined to the liver, including treatment strategies for patients without extrahepatic spread.
- Tebentafusp
- HLA-A02:01-selected treatment
- Liver metastases
- Pathological complete response
Clinical interest also extends to patients receiving treatment after prior systemic or liver-directed therapy, with a focus on tumour control in hepatic metastatic disease.
Advanced melanoma and systemic immunotherapy
Trials in advanced melanoma examine combinations of immunotherapy and targeted agents for broader disease control across later-stage melanoma settings.
- Pembrolizumab
- Enfortumab vedotin
- Objective response rate
- RECIST 1.1
The sponsor’s portfolio includes treatment approaches aimed at improving outcomes in advanced cutaneous melanoma through combination-based systemic therapy.
BRAF-mutated melanoma with brain metastases
One research area addresses BRAF-mutated melanoma complicated by symptomatic brain metastases, with attention to disease control in the central nervous system.
- Encorafenib
- Binimetinib
- Cemiplimab
- Fianlimab
These studies reflect interest in sequencing targeted therapy and immune checkpoint blockade for patients with intracranial involvement.
Multicentre melanoma care and translational oncology
The sponsor supports multicentre clinical research across Spain and other active sites, with a focus on melanoma subtypes that require specialised oncologic management.
- Melanoma
- Uveal melanoma
- Metastatic disease
- Collaborative research sites
Its trial activity spans ocular melanoma, advanced-stage disease, and metastatic spread requiring coordinated specialist care.
